Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature.
- Author:
Ya GAO
1
;
Baohong PING
;
Shuyun ZHOU
Author Information
1. Huiqiao Department, Southern Medical University, Guangzhou, China. xiaoya_729@yahoo.com.cn
- Publication Type:Case Reports
- MeSH:
Azacitidine;
analogs & derivatives;
therapeutic use;
DNA Modification Methylases;
antagonists & inhibitors;
Female;
Humans;
Middle Aged;
Myelodysplastic Syndromes;
drug therapy
- From:
Journal of Southern Medical University
2012;32(2):280-282
- CountryChina
- Language:Chinese
-
Abstract:
Findings in epigenetic changes in meylodysplastic syndromes (MDS) and the development of demethylating drugs provide a new approach to the treatment of MDS. We used standard-dose decitabine for treatment of MDS in an elderly patient with an International Prostate Symptom Score (IPSS) of moderate risk group 2, and achieved a complete response in the first course. We report our experience with this case and review the relevant literatures.
